Abstract: The present invention provides an improved method of producing highly pure retinal pigment epithelial (RPE) cells by differentiation of pluripotent stem cells.

Abstract: The present invention relates to a pharmaceutical composition for Alzheimer's treatment containing as an active ingredient of late-stage human mesenchymal stem cells induced into glia-like cells (ghMSCs). When the glia-like cells differentiated from the late-stage human mesenchymal stem cells were co-cultured with neural stem cells having toxicity induced by amyloid beta, effects of increasing the reduced viability and proliferative potential of the neural stem cells and reducing the increased cytotoxicity of the neural stem cells were verified. In addition, the expression of inflammasomes is reduced, and effects of improving long-term memory with respect to spatial perception ability and enhancing spatial cognitive ability in Alzheimer-induced mouse models were verified. Therefore, the pharmaceutical composition of the present invention can be advantageously used in Alzheimer's treatment.

Abstract: The present invention relates to a pharmaceutical composition comprising glia-like cells differentiated from human mesenchymal stem cells as an active ingredient for treatment of stroke. Specifically, as a result of injecting the glia-like cells differentiated from human mesenchymal stem cells (ghMSCs) of the present invention to cerebral infarction-induced animal models, the infarct volume remarkably decreased by 50% or more and neural functions were remarkably improved, compared to a control group and a group treated with human mesenchymal stem cells (hMSCs), demonstrating that ischemic stroke (infarction) is treated by the Akt pathway of IGFBP-4 via IGF-1R. Thus, the differentiated glia-like cells of the present invention can be advantageously used as a cell therapy product for stroke.

Abstract: A cell composition includes neural stem cells and neural stem cells derived from mesenchymal stem cells, and at least one selected from the group consisting of immature neural stem cells and mesenchymal stem cells. The number of the neural stem cells is at least 70% of the number of the cells included in the cell composition, and the total number of the cells of the immature neural stem cells and the mesenchymal stem cells is at most 30% of the number of the cells included in the cell composition. The cell composition has a very low probability of being developed into a cancer cell and thus can be used as a cell therapeutic.

Abstract: A method for differentiation of neural stem cells, neurons and GABAergic neurons from mesenchymal stem cells includes culturing the mesenchymal stem cells in a medium containing SB431542, Noggin and LDN193189. By this method, the mesenchymal stem cells are differentiated into neural stem cells, neurons and GABAergic neurons at a high transformation rate without gene manipulation.

Abstract: A method for differentiation of neural stem cells, neurons and GABAergic neurons from mesenchymal stem cells includes culturing the mesenchymal stem cells in a medium containing SB431542, Noggin and LDN193189. By this method, the mesenchymal stem cells are differentiated into neural stem cells, neurons and GABAergic neurons at a high transformation rate without gene manipulation.

Abstract: The present invention relates to a neuronal regeneration material screening method using ex vivo models, more precisely a neuronal regeneration material screening method using an organotypic spinal cord slice culture. The neuronal regeneration material screening method using spinal cord slices of living bodies of the present invention can be effectively applied for the development of a novel therapeutics for neurodegenerative diseases, such as spinal cord injury.

Abstract: The present invention relates to a neuronal regeneration material screening method using ex vivo models, more precisely a neuronal regeneration material screening method using an organotypic spinal cord slice culture. The neuronal regeneration material screening method using spinal cord slices of living bodies of the present invention can be effectively applied for the development of a novel therapeutics for neurodegenerative diseases, such as spinal cord injury.

Abstract: The present invention relates to a method for inducing differentiation of bone marrow-derived mesenchymal stem cells into mature neurons by culturing them in an optimal medium supplemented with necessary composition. According to the pre-induction method of the invention and a method for inducing differentiation of mesenchymal stem cells into neurons by culturing them in neuronal induction media (NIM) containing butyl hydroxyanisole, forskolin and VPA, mesenchymal stem cells can be effectively differentiated into neurons or motor neurons, which thereby can be effectively used as a therapeutic agent for cell therapy for neurodegenerative diseases.